title: Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine.
abstract: In order to impede the increase in pertussis incidence in the adolescent group, a school-leaving booster dose administered at the age of 14 to 16 years will be introduced in Sweden in 2016. Preceding this introduction, an open-label, randomized, multicenter, clinical trial without a control group and with blinded analysis was performed, investigating both safety and immunogenicity. Reported here are the memory B-cell and serological responses detected in a smaller cohort (n = 34) of the 230 subjects recruited to the study. All subjects had received primary vaccination consisting of three doses of diphtheria-tetanus-5-component pertussis (DTaP5) vaccine, at 3, 5, and 12 months of age, and a tetanus-low-dose diphtheria-5-component pertussis (Tdap5) vaccine booster at 5.5 years. In this study, the subjects were randomly assigned and received either a Tdap1 or Tdap5 booster. Of the 230 participants, 34 subjects had samples available for evaluation of IgG-producing memory B-cell responses. Both vaccine groups had significant increases in pertussis toxin-specific serum IgG levels, but only the 1-component group showed significant increases in pertussis toxin-specific memory B cells. The 5-component group had significant increases in filamentous hemagglutinin- and pertactin-specific memory B-cell and serum IgG levels; these were not seen in the 1-component group, as expected. In conclusion, this study shows that a 5th consecutive dose of an acellular pertussis vaccine induces B-cell responses in vaccinated adolescents. (This study has been registered at EudraCT under registration no. 2008-008195-13 and at ClinicalTrials.gov under registration no. NCT00870350.).
authors.affiliation: The Public Health Agency of Sweden, Solna, Sweden Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden maja.jahnmatz@folkhalsomyndigheten.se.
authors.forename: Maja
authors.initials: M
authors.lastname: Jahnmatz
authors.affiliation: The Public Health Agency of Sweden, Solna, Sweden.
authors.forename: Margaretha
authors.initials: M
authors.lastname: Ljungman
authors.affiliation: The Public Health Agency of Sweden, Solna, Sweden.
authors.forename: Eva
authors.initials: E
authors.lastname: Netterlid
authors.affiliation: Division of Inflammation Medicine, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
authors.forename: Maria C
authors.initials: MC
authors.lastname: Jenmalm
authors.affiliation: The Public Health Agency of Sweden, Solna, Sweden Allergy Centre, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
authors.forename: Lennart
authors.initials: L
authors.lastname: Nilsson
authors.affiliation: The Public Health Agency of Sweden, Solna, Sweden.
authors.forename: Rigmor
authors.initials: R
authors.lastname: Thorstensson
mesh_terms: D018829:Adhesins, Bacterial / Q000276:immunology; D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood*; D016175:B-Lymphocyte Subsets / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods*; D007074:Immunoglobulin G / Q000097:blood*; D007156:Immunologic Memory; D008297:Male; D013548:Sweden; D016896:Treatment Outcome; D010566:Virulence Factors, Bordetella / Q000276:immunology; D014917:Whooping Cough / Q000276:immunology / Q000517:prevention & control*
chemical_list: D018829:Adhesins, Bacterial; D000914:Antibodies, Viral; D001425:Bacterial Outer Membrane Proteins; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D007074:Immunoglobulin G; D010566:Virulence Factors, Bordetella; C065273:filamentous hemagglutinin adhesin, Bordetella pertussis; C068929:pertactin